BMO Capital Markets Raises Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $200.00

Sarepta Therapeutics (NASDAQ:SRPT) had its price objective upped by BMO Capital Markets from $170.00 to $200.00 in a report issued on Monday morning, Benzinga reports. They currently have an outperform rating on the biotechnology company’s stock.

A number of other research firms have also recently weighed in on SRPT. Mizuho lifted their price objective on Sarepta Therapeutics from $145.00 to $179.00 and gave the company a buy rating in a research report on Friday, May 17th. JPMorgan Chase & Co. reduced their price objective on shares of Sarepta Therapeutics from $177.00 to $175.00 and set an overweight rating for the company in a research note on Friday, May 3rd. TheStreet upgraded shares of Sarepta Therapeutics from a d rating to a c- rating in a research report on Monday, March 4th. Piper Sandler reaffirmed an overweight rating and issued a $157.00 target price on shares of Sarepta Therapeutics in a report on Friday, June 21st. Finally, Robert W. Baird raised their price target on Sarepta Therapeutics from $170.00 to $200.00 and gave the company an outperform rating in a report on Friday, June 21st. Five analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of Moderate Buy and an average target price of $185.06.

Sarepta Therapeutics Stock Performance

SRPT opened at $157.96 on Monday. Sarepta Therapeutics has a 12-month low of $55.25 and a 12-month high of $173.25. The company has a market cap of $14.93 billion, a price-to-earnings ratio of 1,436.00 and a beta of 0.96. The company has a current ratio of 4.05, a quick ratio of 3.44 and a debt-to-equity ratio of 1.18. The company’s 50 day moving average is $128.90 and its 200 day moving average is $121.71.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported $0.73 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.84. Sarepta Therapeutics had a net margin of 1.20% and a return on equity of 2.20%. The firm had revenue of $413.50 million during the quarter, compared to the consensus estimate of $375.52 million. During the same quarter in the previous year, the firm posted ($1.44) EPS. The company’s revenue for the quarter was up 63.1% compared to the same quarter last year. On average, equities research analysts predict that Sarepta Therapeutics will post 3.71 EPS for the current year.

Insider Buying and Selling at Sarepta Therapeutics

In other news, insider Dallan Murray sold 3,635 shares of the business’s stock in a transaction dated Thursday, May 2nd. The shares were sold at an average price of $140.00, for a total value of $508,900.00. Following the sale, the insider now directly owns 18,125 shares in the company, valued at approximately $2,537,500. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In related news, EVP Ryan Edward Brown sold 38,957 shares of the stock in a transaction on Tuesday, June 25th. The stock was sold at an average price of $161.61, for a total transaction of $6,295,840.77. Following the sale, the executive vice president now owns 17,129 shares in the company, valued at approximately $2,768,217.69. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Dallan Murray sold 3,635 shares of the firm’s stock in a transaction on Thursday, May 2nd. The stock was sold at an average price of $140.00, for a total value of $508,900.00. Following the completion of the sale, the insider now owns 18,125 shares of the company’s stock, valued at $2,537,500. The disclosure for this sale can be found here. Insiders sold 50,451 shares of company stock worth $8,086,386 over the last 90 days. 7.70% of the stock is owned by insiders.

Institutional Investors Weigh In On Sarepta Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Principal Securities Inc. bought a new position in Sarepta Therapeutics during the 4th quarter valued at about $26,000. Mather Group LLC. bought a new position in shares of Sarepta Therapeutics during the first quarter valued at approximately $28,000. Riggs Asset Managment Co. Inc. raised its holdings in shares of Sarepta Therapeutics by 125.0% in the first quarter. Riggs Asset Managment Co. Inc. now owns 225 shares of the biotechnology company’s stock worth $29,000 after buying an additional 125 shares during the period. Cary Street Partners Investment Advisory LLC lifted its stake in shares of Sarepta Therapeutics by 154.0% during the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 254 shares of the biotechnology company’s stock worth $31,000 after acquiring an additional 154 shares during the last quarter. Finally, New Covenant Trust Company N.A. purchased a new position in Sarepta Therapeutics during the 1st quarter valued at $32,000. Hedge funds and other institutional investors own 86.68% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.